Remoxipride
Remoxipride is a selective dopamine D2 and D3 receptor antagonist antipsychotic of the benzamide class with a pharmacological profile similar to raclopride, demonstrating antipsychotic efficacy with a lower propensity for extrapyramidal side effects than typical antipsychotics. It was withdrawn from the market due to an association with aplastic anemia, a rare but potentially fatal bone marrow failure condition.
Peso molecular
371,2700 g/mol
LogP
2,10
TPSA
50,80 Ų
Regla de cinco de Lipinski
Cumple
Mecanismo de acción
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC
InChI
InChI=1S/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)/t11-/m0/s1
Molecular Formula
C16H23BrN2O3
HBD / HBA
1 / 4
Enlaces Rotables
6
Átomos Pesados
22
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
Remoxipride is a selective dopamine D2 and D3 receptor antagonist antipsychotic of the benzamide class with a pharmacological profile similar to raclopride, demonstrating antipsychotic efficacy with a lower propensity for extrapyramidal side effects than typical antipsychotics. It was withdrawn from the market due to an association with aplastic anemia, a rare but potentially fatal bone marrow failure condition.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Remoxipride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL22242. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 54477. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="remoxipride"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/remoxipride/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/remoxipride/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/remoxipride/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="remoxipride"></drugfyi-drug>